Hubei Biocause Pharmaceutical (000627) — Tangible Net Worth Ratio
Hubei Biocause Pharmaceutical (000627) has a Tangible Net Worth Ratio of 99.3% as of September 2024. This metric is calculated by deducting intangible assets (CN¥259.99 Million) from net assets (CN¥36.00 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See Hubei Biocause Pharmaceutical (000627) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Hubei Biocause Pharmaceutical Tangible Net Worth Ratio (2000–2023)
This chart shows how Hubei Biocause Pharmaceutical's Tangible Net Worth Ratio has changed across 24 annual periods from 2000 to 2023. As of September 2024, the ratio stands at 99.3%, reflecting net assets of CN¥36.00 Billion with intangible assets of CN¥259.99 Million CNY. See Hubei Biocause Pharmaceutical defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Tangible Net Worth Ratio for Hubei Biocause Pharmaceutical (2000–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Hubei Biocause Pharmaceutical (000627) total market value.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 99.2% | CN¥33.63 Billion | CN¥283.20 Million | CN¥301.94 Billion | ▲ +0.0 pp |
| 2022 | 99.1% | CN¥34.60 Billion | CN¥299.34 Million | CN¥288.60 Billion | ▼ -0.1 pp |
| 2021 | 99.3% | CN¥37.47 Billion | CN¥269.71 Million | CN¥263.90 Billion | ▼ -0.2 pp |
| 2020 | 99.5% | CN¥34.59 Billion | CN¥190.00 Million | CN¥239.40 Billion | ▼ -0.2 pp |
| 2019 | 99.7% | CN¥34.35 Billion | CN¥109.42 Million | CN¥205.27 Billion | ▲ +0.5 pp |
| 2018 | 99.2% | CN¥26.01 Billion | CN¥213.35 Million | CN¥178.25 Billion | ▲ +1.1 pp |
| 2017 | 98.1% | CN¥26.70 Billion | CN¥519.90 Million | CN¥140.42 Billion | ▲ +0.7 pp |
| 2016 | 97.3% | CN¥20.40 Billion | CN¥549.06 Million | CN¥117.88 Billion | ▲ +24.8 pp |
| 2015 | 72.5% | CN¥1.78 Billion | CN¥490.45 Million | CN¥2.41 Billion | ▲ +6.3 pp |
| 2014 | 66.2% | CN¥1.49 Billion | CN¥503.88 Million | CN¥2.11 Billion | ▼ -32.7 pp |
| 2013 | 98.9% | CN¥1.44 Billion | CN¥15.54 Million | CN¥2.16 Billion | ▲ +0.2 pp |
| 2012 | 98.7% | CN¥1.54 Billion | CN¥19.73 Million | CN¥2.06 Billion | ▲ +0.1 pp |
| 2011 | 98.6% | CN¥1.41 Billion | CN¥19.71 Million | CN¥1.88 Billion | ▲ +0.4 pp |
| 2010 | 98.3% | CN¥1.60 Billion | CN¥28.02 Million | CN¥1.98 Billion | ▲ +0.3 pp |
| 2009 | 98.0% | CN¥1.57 Billion | CN¥32.07 Million | CN¥2.16 Billion | ▲ +0.2 pp |
| 2008 | 97.8% | CN¥1.51 Billion | CN¥33.40 Million | CN¥1.98 Billion | ▲ +1.9 pp |
| 2007 | 95.9% | CN¥866.03 Million | CN¥35.34 Million | CN¥1.32 Billion | ▼ -0.2 pp |
| 2006 | 96.1% | CN¥723.71 Million | CN¥28.19 Million | CN¥1.17 Billion | ▲ +0.4 pp |
| 2005 | 95.7% | CN¥731.23 Million | CN¥31.63 Million | CN¥1.09 Billion | ▲ +21.5 pp |
| 2004 | 74.2% | CN¥723.91 Million | CN¥186.79 Million | CN¥1.08 Billion | ▲ +0.5 pp |
| 2003 | 73.7% | CN¥718.75 Million | CN¥189.07 Million | CN¥1.09 Billion | ▼ -2.3 pp |
| 2002 | 76.0% | CN¥768.02 Million | CN¥184.43 Million | CN¥1.09 Billion | ▼ -7.8 pp |
| 2001 | 83.8% | CN¥762.99 Million | CN¥123.54 Million | CN¥989.09 Million | ▲ +1.5 pp |
| 2000 | 82.3% | CN¥594.52 Million | CN¥105.05 Million | CN¥886.33 Million | — |